Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Vertongen

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Peptides|January 1, 1997
Development of high affinity selective VIP1 receptor agonistsP Gourlet, A Vandermeers, P Vertongen, et al.
Gut|May 1, 1995
Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumoursJ L Van Laethem, P Vertongen, J Deviere, et al.
Journal of Cellular Physiology|April 1, 1996
Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomasP Vertongen, C Devalck, E Sariban, et al.
Molecular and Cellular Endocrinology|January 1, 1995
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptorC Delporte, P Poloczek, P de Neef, et al.
Peptides|January 1, 1997
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclassP Gourlet, P Vertongen, A Vandermeers, et al.
Gastroenterology|June 1, 1995
Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitisJ L van Laethem, J Deviere, A Resibois, et al.
Neuropeptides|December 31, 1997
Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissuesP Vertongen, P De Clerck, J C Fournet, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1993
Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomasP Robberecht, P Vertongen, B Velkeniers, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Peptides|January 1, 1997
Development of high affinity selective VIP1 receptor agonistsP Gourlet, A Vandermeers, P Vertongen, et al.
Gut|May 1, 1995
Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumoursJ L Van Laethem, P Vertongen, J Deviere, et al.
Journal of Cellular Physiology|April 1, 1996
Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomasP Vertongen, C Devalck, E Sariban, et al.
Molecular and Cellular Endocrinology|January 1, 1995
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptorC Delporte, P Poloczek, P de Neef, et al.
Peptides|January 1, 1997
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclassP Gourlet, P Vertongen, A Vandermeers, et al.
Gastroenterology|June 1, 1995
Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitisJ L van Laethem, J Deviere, A Resibois, et al.
Neuropeptides|December 31, 1997
Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissuesP Vertongen, P De Clerck, J C Fournet, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1993
Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomasP Robberecht, P Vertongen, B Velkeniers, et al.
Pageof 4